NBI 77860 clinical trials
Also written GSK561679.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses NBI 77860 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 3
GlaxoSmithKline (5) · VA Office of Research and Development (1) · Emory University (1) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1) · Neurocrine Biosciences (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses NBI 77860 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Analyzing Female Trauma Exposed Responses to a MedicationCompletedPhase 2VA Office of Research and DevelopmentNCT01814332Written as GSK561679How we know
- A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive DisorderCompletedPhase 2GlaxoSmithKlineNCT00733980Written as GSK561679How we know
- To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.CompletedPhase 1GlaxoSmithKlineNCT00426608Written as GSK561679How we know
- A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety DisorderCompletedPhase 1GlaxoSmithKlineNCT00555139Written as GSK561679 tabletHow we know
- Evaluation of GSK561679 in Women With Post-Traumatic Stress DisorderCompletedPhase 2Emory UniversityNCT01018992Written as GSK561679How we know
- CRF1 Antagonist GSK561679 in AlcoholismCompletedPhase 2National Institute on Alcohol Abuse and Alcoholism (NIAAA)NCT01187511Written as GSK561679How we know
- Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal HyperplasiaWithdrawnPhase 1Neurocrine BiosciencesNCT02349503Written as NBI-77860How we know
- A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679WithdrawnPhase 2GlaxoSmithKlineNCT00511563Written as GW876008 and GSK561679How we know
- A Study to Examine the Absorption of GSK561679 in Healthy Male VolunteersCompletedPhase 1GlaxoSmithKlineNCT00539136Written as GSK561679 tablet or solutionHow we know